anzemet dolasetron mesilate 12.5mg/0.625ml injection vial
sanofi-aventis australia pty ltd - dolasetron mesilate monohydrate -
anzemet- dolasetron mesylate tablet, film coated
validus pharmaceuticals llc - dolasetron mesylate (unii: u3c8e5bwkr) (dolasetron - unii:82wi2l7q6e) - dolasetron mesylate 50 mg - anzemet tablets are indicated for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses in adults and children 2 years and older. anzemet tablets are contraindicated in patients known to have hypersensitivity to the drug.
anzemet dolasetron mesylate tablet film coated
avera mckennan hospital - dolasetron mesylate (unii: u3c8e5bwkr) (dolasetron - unii:82wi2l7q6e) - dolasetron mesylate 100 mg
anzemet dolasetron mesylate injection
sanofi-aventis u.s. llc - dolasetron mesylate (unii: u3c8e5bwkr) (dolasetron - unii:82wi2l7q6e) - dolasetron mesylate 12.5 mg in 0.625 ml
anzemet dolasetron mesylate tablet film coated
sanofi-aventis u.s. llc - dolasetron mesylate (unii: u3c8e5bwkr) (dolasetron - unii:82wi2l7q6e) - dolasetron mesylate 50 mg
anzemet dolasetron mesilate 50mg tablet blister pack
sanofi-aventis australia pty ltd - dolasetron mesilate monohydrate -
anzemet tablet
sanofi-aventis canada inc - dolasetron mesylate - tablet - 50mg - dolasetron mesylate 50mg - 5-ht3 receptor antagonists
anzemet tablet
sanofi-aventis canada inc - dolasetron mesylate - tablet - 100mg - dolasetron mesylate 100mg - 5-ht3 receptor antagonists
anzemet injection 20 mg/ml solution
sanofi-aventis canada inc - dolasetron mesylate - solution - 20mg - dolasetron mesylate 20mg - 5-ht3 receptor antagonists
zamanon 200 mg tablets
aventis pharma (pty) limited - dolasetron mesilate - tablets - dolasetron mesilate tablets 200 mg